Compare RILYP & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RILYP | MRK |
|---|---|---|
| Founded | 1973 | 2000 |
| Country | United States | United States |
| Employees | 2056 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 260.2B |
| IPO Year | N/A | N/A |
| Metric | RILYP | MRK |
|---|---|---|
| Price | $3.60 | $99.74 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $109.13 |
| AVG Volume (30 Days) | 38.1K | ★ 15.8M |
| Earning Date | 01-01-0001 | 10-30-2025 |
| Dividend Yield | ★ 7.03% | 3.39% |
| EPS Growth | N/A | ★ 58.08 |
| EPS | N/A | ★ 7.56 |
| Revenue | $854,383,000.00 | ★ $64,235,000,000.00 |
| Revenue This Year | N/A | $1.97 |
| Revenue Next Year | N/A | $4.96 |
| P/E Ratio | ★ N/A | $13.27 |
| Revenue Growth | N/A | ★ 1.68 |
| 52 Week Low | $1.73 | $73.31 |
| 52 Week High | $20.00 | $105.84 |
| Indicator | RILYP | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 30.59 | 59.78 |
| Support Level | $3.74 | $96.06 |
| Resistance Level | $3.97 | $99.85 |
| Average True Range (ATR) | 0.28 | 2.46 |
| MACD | -0.04 | -0.70 |
| Stochastic Oscillator | 23.77 | 43.03 |
B. Riley Financial Inc is a diversified financial services company. The company through its subsidiaries offers investment banking and financial services to corporate, institutional, and high-net-worth clients and also asset disposition, valuation and appraisal, and capital advisory services to retail, wholesale, institutional, lenders, capital providers, private equity investors, and professional services firms in United States, Canada, and Europe. It also provides internet access and subscription services. The reportable operating segments of the company include Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications segment, and Consumer products segment.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).